VCP
SAGE

Verus Capital Partners’s Sage Therapeutics SAGE Stock Holding History

Verus Capital Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$50K Buy
1,724
+1,382
+404% +$80K 0.02% 498
2019
Q4 		$25K Buy
+342
New +$42.1K 0.01% 826

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Verus Capital Partners's SAGE Position: Q1 2020 in Review

Verus Capital Partners increased its Sage Therapeutics (SAGE) stake by 404% in Q1 2020, buying an estimated $80K and bringing the position to 1,724 shares worth $50K. The position accounts for 0.02% of the portfolio, ranked #498.

Verus Capital Partners first reported a position in SAGE in Q4 2019 and has held it in 2 quarters since. 229 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

  • Verus Capital Partners held 1,724 shares of Sage Therapeutics worth $50K as of Q1 2020.
  • Verus Capital Partners bought 1,382 Sage Therapeutics shares in Q1 2020, an estimated $80K.
  • Sage Therapeutics made up 0.02% of Verus Capital Partners's portfolio in Q1 2020, its #498 holding.
  • Verus Capital Partners first reported a position in Sage Therapeutics in Q4 2019 and has held it in 2 quarters since.
  • 229 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.